Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Company Overview

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Key Stats

• Today's Range: $3.13 to $3.27
• 50-Day Range: $2.76 to $14.85
• 52-Week Range: $2.66 to $16.00
• Volume: 122,316 shs
• Average Volume: 411,559 shs
• Market Capitalization: $60.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.75
• Consensus Rating: Moderate Buy

Elicio Therapeutics Stock Analysis - MarketRank™

Elicio Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 613th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elicio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Elicio Therapeutics has a consensus price target of $19.75, representing about 519.1% upside from its current price of $3.19.

Amount of Analyst Coverage

Elicio Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Elicio Therapeutics are expected to decrease in the coming year, from ($2.08) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elicio Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elicio Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elicio Therapeutics has a P/B Ratio of 35.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.02% of the float of Elicio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Elicio Therapeutics has a short interest ratio ("days to cover") of 1.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elicio Therapeutics has recently increased by 8.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elicio Therapeutics does not currently pay a dividend.

Dividend Growth

Elicio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Elicio Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for ELTX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

MarketBeat Follows

2 people have added Elicio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.03% of the stock of Elicio Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 8/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELTX
• CIK: 1555192
• Web: www.angion.com
• Phone: 415-655-4899
• Fax: N/A
• Employees: N/A
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Elicio Therapeutics: $19.75
• High Price Target: $27.00
• Low Price Target: $12.00
• Potential Upside/Downside: +519.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.57 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,748.16%
• Return on Assets: -151.12%

Debt

• Debt-to-Equity Ratio: 5.75
• Current Ratio: 2.24
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.09 per share
• Price / Book: 35.44

Miscellaneous

• Outstanding Shares: 19,090,000
• Free Float: 9,371,000
• Market Cap: $60.90 million
• Optionable: Not Optionable
• Beta: 1.30